25,764 Shares in Prothena Co. plc (NASDAQ:PRTA) Bought by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd bought a new position in shares of Prothena Co. plc (NASDAQ:PRTA) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,764 shares of the biotechnology company’s stock, valued at approximately $432,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Prothena by 5.1% during the first quarter. Vanguard Group Inc. now owns 1,125,283 shares of the biotechnology company’s stock worth $27,873,000 after acquiring an additional 54,728 shares in the last quarter. Armistice Capital LLC boosted its stake in Prothena by 42.3% during the second quarter. Armistice Capital LLC now owns 1,560,000 shares of the biotechnology company’s stock worth $32,198,000 after acquiring an additional 464,000 shares in the last quarter. SG Americas Securities LLC boosted its stake in Prothena by 226.4% during the second quarter. SG Americas Securities LLC now owns 54,572 shares of the biotechnology company’s stock worth $1,126,000 after acquiring an additional 37,852 shares in the last quarter. Federated Hermes Inc. acquired a new position in Prothena during the second quarter worth $905,000. Finally, Duncan Williams Asset Management LLC acquired a new position in Prothena during the third quarter worth $816,000. 97.08% of the stock is owned by institutional investors.

Prothena Stock Up 2.1 %

Shares of NASDAQ:PRTA opened at $16.21 on Friday. The firm has a market capitalization of $872.24 million, a PE ratio of -6.54 and a beta of 0.16. Prothena Co. plc has a twelve month low of $13.22 and a twelve month high of $41.54. The company has a 50-day moving average price of $17.02 and a two-hundred day moving average price of $19.87.

Prothena (NASDAQ:PRTA) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.08. The firm had revenue of $0.97 million during the quarter, compared to analyst estimates of $1.22 million. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The company’s quarterly revenue was down 98.9% on a year-over-year basis. During the same quarter last year, the business earned $0.38 earnings per share. Analysts anticipate that Prothena Co. plc will post -2.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on PRTA shares. Oppenheimer lowered their target price on shares of Prothena from $66.00 to $62.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a research report on Monday, September 30th. HC Wainwright restated a “buy” rating and set a $84.00 price target on shares of Prothena in a research report on Wednesday, November 13th. Royal Bank of Canada reduced their price target on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. Finally, StockNews.com lowered shares of Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $61.86.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.